Last updated: 2026-09-16 10:31:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
BioCardia, Inc. (BCDA) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $1.24, with a market capitalisation of $18.02M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.75 to $2.05. This page covers its latest market performance, valuation, price trends and company information.
$18.02M | |
$1.23 | |
$129.00 | |
$0.75 | |
$1.23 | |
189.00 | |
499.50K | |
-- | |
$2.05 | |
$0.75 | |
-- | |
-- |
BioCardia, Inc. (BCDA) is trading at $1.24 in pre-market trading as of 2026-09-16 10:12:00, up 0.89% ($0.01) from the previous close of $1.23
Pre-market trading shows how investors are pricing BCDA before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, BioCardia, Inc. (BCDA) moved from $1.08 to $1.24, representing a gain of 14.91% ($0.16).
The stock traded between $1.06 and $1.30 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 230.29 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 37.8%
BCDA is currently trading at $1.24, placing it 37.8% of the way from its 52-week low of $0.75 to its 52-week high of $2.05. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 21 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of BioCardia, Inc. (BCDA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.